Titan Pharmaceuticals
American pharmaceutical company
From Wikipedia, the free encyclopedia
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds.[3] In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.[2][4]
| |
| Type | Public |
|---|---|
| Nasdaq: TTNP | |
| Industry | Pharmaceuticals |
| Headquarters | California |
Key people | |
| Revenue |  $1.7 million[2] |
| Total assets | $8.4 million[2] |
Number of employees | 14 (Nov 2018) |
| Website | titanpharm |
Titan's principal asset is Probuphine,[5][6] a slow-release implant formulation of buprenorphine[7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.[8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.[6]
History
The company was founded in 1992 and is headquartered in San Francisco, California.
In August 2022, David Lazar was appointed chairman and CEO.[9] He succeeded Marc Rubin, who had held the position since October 2007.[10]
In 2024, the company entered into a merger agreement and became a wholly owned subsidiary of BSKE Ltd.[11]
